Insmed (NASDAQ:INSM – Get Free Report) and Fate Therapeutics (NASDAQ:FATE – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.
Analyst Ratings
This is a breakdown of current ratings and target prices for Insmed and Fate Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Insmed | 1 | 0 | 22 | 2 | 3.00 |
| Fate Therapeutics | 1 | 3 | 4 | 0 | 2.38 |
Insmed currently has a consensus price target of $205.52, indicating a potential upside of 62.74%. Fate Therapeutics has a consensus price target of $5.90, indicating a potential upside of 137.90%. Given Fate Therapeutics’ higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than Insmed.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Insmed | $606.42 million | 45.48 | -$1.28 billion | ($4.11) | -30.73 |
| Fate Therapeutics | $6.65 million | 44.68 | -$136.32 million | ($1.05) | -2.36 |
Fate Therapeutics has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Insmed and Fate Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Insmed | -76.94% | -123.94% | -44.30% |
| Fate Therapeutics | -1,941.09% | -65.08% | -41.73% |
Risk and Volatility
Insmed has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500.
Insider and Institutional Ownership
97.5% of Fate Therapeutics shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Fate Therapeutics beats Insmed on 9 of the 15 factors compared between the two stocks.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
